The Toronto Hypertrophic Cardiomyopathy (HCM) Genotype Score and Mayo HCM Genotype Predictor are risk assessment models developed to estimate a patient's likelihood of testing positive for a pathogenic variant causative of HCM. These models were developed from adult populations with HCM based on factors that have been associated with a positive genotype and have not been validated in external populations. The purpose of this study was to evaluate the overall predictive abilities of these models in a clinical pediatric HCM setting. A retrospective medical record review of 77 pediatric patients with gene panel testing for HCM between September 2005 and June 2015 was performed. Clinical and echocardiographic variables used in the developed models were collected and used to calculate scores for each patient. To evaluate model performance, the ability to discriminate between a carrier and non-carrier was assessed by area under the ROC curve (AUC) and overall calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit statistic. Discrimination assessed by AUC was 0.72 (P < 0.001) for the Toronto model and 0.67 (P = 0.004) for the Mayo model. The Toronto model and the Mayo model showed P values of 0.36 and 0.82, respectively, for model calibration. Our findings suggest that these models are useful in predicting a positive genetic test result in a pediatric HCM setting. They may be used to aid healthcare providers in communicating risk and enhance patient decision-making regarding pursuit of genetic testing.
Introduction
Hypertrophic cardiomyopathy (HCM) is among the most commonly inherited cardiovascular diseases, with an estimated prevalence of ~ 1:500 individuals [1] . It is characterized by unexplained hypertrophy of the ventricles in the absence of an underlying condition or other cardiac disease, such as valvular heart disease or hypertension [2, 3] . HCM has a broad spectrum of phenotypic variability with respect to age of onset, degree of hypertrophy, symptoms, and other clinical manifestations. It is genetically heterogeneous, and multiple pathogenic variants have been identified, with the majority of them inherited in an autosomal dominant manner.
Genetic testing for HCM has become progressively widespread since the discovery of the first HCM-associated gene identified in 1990 [4] . Current testing allows for identification of pathogenic variants in more than 20 genes [2] . Previous studies suggest that pathogenic variants can be identified in approximately 30-68% of individuals with HCM [5] [6] [7] [8] . Pediatric studies in particular have revealed overall genetic testing yields ranging from 21 to 53% [9] [10] [11] [12] .
Clinical genetic testing for HCM can be useful in confirmation of disease etiology and risk stratification of family members through targeted variant testing. It is also valuable in identifying HCM phenocopies (e.g., Fabry disease, Noonan syndrome, mitochondrial cardiomyopathies). Several academic and commercial laboratories offer gene panel testing for HCM, in which the cost varies considerably. Studies have suggested that implementing genetic testing into the management of families with HCM is cost-effective when compared solely to a serial cardiac screening approach [13, 14] . Based on the impact of clinical and family care, as well as probable cost savings, it has been suggested that families with HCM be referred to specialized cardiac genetic clinics that can offer genetic counseling and testing. Published guidelines from multiple organizations support the use of genetic testing in probands with a clinical diagnosis of HCM [15] [16] [17] .
A number of factors influence the yield of genetic testing for HCM, such as family history and age at diagnosis. Several investigators have suggested that the generation of a patient-specific pre-test probability of a positive test result could aid healthcare providers in conveying appropriate genetic risk assessment. Additionally, this could enhance decision-making for patients and families.
Risk prediction models to estimate a patient's likelihood of carrying a pathogenic variant are not a novel concept and have shown to inform pre-test genetic counseling and testing. Several models have been developed and validated in the setting of hereditary cancer, which suggests their clinical usefulness in the ability to discriminate between a carrier and a non-carrier. The models are widely used in the context of genetic counseling and testing for individuals suspected to have Hereditary Breast and Ovarian Cancer Syndrome or Lynch Syndrome, for example [18, 19] .
Groups from Toronto General Hospital and Mayo Clinic developed separate prediction tools to identify the probability that an individual patient with clinically diagnosed HCM would be genotype-positive. These published prediction models are known as the Toronto HCM Genotype Score and the Mayo HCM Genotype Predictor [20, 21] .
Description of Models
Toronto HCM Genotype Score [20] -The Toronto HCM Genotype Score was developed with the aim to construct a score identifying individuals with a high likelihood of having a positive HCM gene panel test result. The study sample consisted of 471 adult probands (average age 45.2 ± 15.9 years) with a clinical diagnosis of HCM. A retrospective medical record review was performed and data extraction variables were determined based on factors from previous studies that demonstrated a significant association with a positive HCM genotype [5, [22] [23] [24] . Study participants prospectively underwent gene panel testing for HCM through a variety of commercial laboratories between July 2005 and November 2010. Overall, 163 of 471 adult probands tested positive for an HCM-associated variant, resulting in a 35% genetic testing yield.
Multivariate regression analysis revealed six independent variables as predictors for a positive HCM genotype in their cohort. Regression coefficients for each variable were divided by the absolute value of the lowest regression coefficient in the model and then rounded to the nearest integer as risk weights. The sum of the points for each variable comprises a patient's genotype score. Each score corresponds to a specific probability of testing positive for an HCM-associated pathogenic variant and is referred to by the investigators as the Long Model (Supplemental Table 1 ). Specific probability for testing positive for a pathogenic variant causative of HCM can be calculated using the following formula:
For further analysis, the Toronto group also created a Tertiles Long Model (Supplemental Table 2 Clinical data deemed relevant to the HCM diagnosis were collected from participants' medical records. Receiver operating characteristic analysis for continuous variables as well as univariate and multivariate analysis identified five positive predictors and one negative predictor with regard to an HCM-positive genotype (Supplemental Table 3 ). The cumulative score of the six variables is associated with the likelihood that an individual will test positive for an HCM-associated pathogenic variant. The probabilities range from 6% for those with a score of − 1 to 80% for those with a score of 5 (Supplemental Table 4 ).
One recent study from the same institution reviewed a population of patients with HCM (separate from the population in which the models were developed) and suggested that the Mayo HCM Genotype Predictor was successfully validated and clinically useful [25] . The cohort consisted of 198 patients with a mean age of 50.0 ± 19.7 years and an overall genetic testing yield of 51%. The authors attributed the higher yield of 51% (vs. a 34% yield in the original study) to a stronger reported family history of sudden cardiac death and/or HCM as well as the PRKAG2 and LAMP2 genes being analyzed in this validation study and excluded in the original study.
Significance
There is limited information about the predictive abilities of the Toronto HCM Genotype Score and the Mayo HCM Genotype Predictor outside of the populations from which they were developed, with the exception of the aforementioned publication validating the Mayo model. Studies assessing the general validity of the Toronto and Mayo models remain necessary. Furthermore, since both models were developed primarily using adult populations with HCM, little is known about their performance in a pediatric population. In the present study, we tested the predictive abilities of the Toronto HCM Genotype Score and the Mayo HCM Genotype Predictor in a study population of patients less than 18 years of age. Our objective was to assess whether or not the genotype prediction tools had comparable predictive abilities in a pediatric population because there are expected to be fundamental differences between children and adults associated with certain variables/markers used in the models. For example, based on age, children are expected to have a smaller body habitus and smaller heart size than adults; therefore, children and adults may have distinct differences in cardiac measurements associated with variables in the models [e.g., maximum left ventricular wall thickness (MLVWT) used in the Mayo HCM Genotype Predictor]. Additionally, the presence of hypertension is a variable used in both models and is less likely to be observed in children than adults. Finally, all pediatric patients in our study are under the age used as a cut-off for assigning points in both models. By conducting this study, we intended to provide information regarding clinical usefulness of the HCM genotype prediction tools in a pediatric HCM setting.
Methods

Study Population
A retrospective medical record review was performed of patients seen at the Heart Institute at Cincinnati Children's Hospital Medical Center (CCHMC) from September 2005 to June 2015 with a clinical diagnosis of HCM and results of clinical HCM gene panel testing. Genetic testing was routinely offered to probands with HCM as part of their clinical care. Patients were less than 18 years of age at the time of their clinical diagnosis and specimen collection date for genetic testing. Patients were excluded if there was no cardiac imaging accessible prior to a septal reduction therapy, if they had a genetic syndrome known to be associated with left ventricular hypertrophy (LVH), or if they had a congenital heart defect causative of LVH. The variables/markers used in the Toronto and Mayo models to calculate a genotype prediction score were collected for each patient. Study data were collected and managed using REDCap (Research Electronic Data Capture) [26] hosted at CCHMC. REDCap is a secure, web-based application designed to support data capture for research studies. This study was approved by the CCHMC Institutional Review Board.
HCM Gene Panel Testing
Medical record review demonstrated that HCM gene panel testing was ordered through various commercial and academic laboratories. The number of genes analyzed ranged from 5 to 36. Variability was attributed to the laboratory used and timing of testing. Two patients had a gene panel consisting of only five genes. Comparison of the genes included on the 5-gene panel (ACTC2, MYL2, MYL3, or TNNC1) to genes included in the Toronto and Mayo studies showed that less than 2% of the positive findings in those studies were in genes not included on the 5-gene panel. Therefore, the two patients who underwent genetic testing with the 5-gene panel were included in this study despite a smaller number of genes analyzed. Patients were considered to have a positive HCM genotype if their test result was classified as pathogenic or likely pathogenic (i.e., disease-causing, likely disease-causing, and presumed pathogenic). A variant of uncertain significance (VUS) was not considered a positive test result. Benign, likely benign, or presumed benign variants were also considered negative. Genetic variants were reviewed in the ClinVar database [27] to assess if interpretation of pathogenicity was consistent with the original classification at the time of genetic testing. Variants which were originally classified as pathogenic or likely pathogenic but were listed in ClinVar as a VUS by the majority of submitters were not included in the positive genotype group for this study. Variants which were classified as uncertain by one submitter in ClinVar but were classified as pathogenic or likely pathogenic by ≥ 2 other submitters were additionally reviewed in the ExAC Browser [28] to justify classification.
Clinical Data
Relevant clinical information was collected from the medical records to calculate predictive genotype scores for each patient. For each parameter in both models, the respective authors' criteria were used (Supplemental Tables 1 and 3) .
Echocardiograms performed closest to the date of specimen collection for genetic testing were used. If echocardiograms were unavailable, cardiac magnetic resonance imaging (cMRI) closest to the date of specimen collection for genetic testing was used. Morphological subtypes (e.g., sigmoid, reversecurve, apical, and neutral) have been previously defined [22] and were interpreted jointly by two pediatric cardiologists. If a patient's morphological subtype did not fall into one of the previously mentioned categories, it was defined as "other."
Statistical Analyses
Descriptive statistics were used to summarize the demographics and clinical characteristics of the study population. Frequency (percentage) was reported for categorical variables; mean ± standard deviation was reported for continuous variables. In the present study, the binomial marker of interest was a positive HCM genotype. T test was used to test the mean differences between individuals with positive genotypes and those with non-positive genotypes for continuous variables; Fisher's exact test was used for comparison of categorical variables. Genotype prediction scores for both models were calculated for each patient. Logistic regression of positive genotypes was performed on scores for positive genotypes and the predicted positive genotypes from the logistic regression model were compared to the observed positive genotypes at each integer value of the scores. To evaluate model performance, discrimination (the ability to discriminate between an HCM pathogenic variant carrier and a non-carrier) was assessed by area under the ROC curve (AUC) and calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit statistic. All statistical analyses were performed in R Version 3.2.1 [29] .
Mayo HCM Genotype Predictor: MLVWT Marker
The Mayo HCM Genotype Predictor uses MLVWT as one of the clinical markers in their genotype prediction score. Individuals with a MLVWT of 20 millimeters (mm) or greater are assigned one point for that specific marker. Due to a smaller cardiac size in children, this particular measurement may not be attained even in children with severe hypertrophy. We acknowledged that for pediatric patients, the MLVWT z-score may be a more sensitive measurement that would capture children with significant hypertrophy who had an absolute measurement less than 20 mm. ROC analysis was performed to determine the cutoff value of MLVWT z-score in our cohort, which was associated with a positive genotype. The Mayo HCM Genotype Predictor using the cutoff value of MLVWT z-score [for simplicity, this will from hereon be referred to as the Mayo HCM Genotype Predictor (z-score)] was then analyzed as well as the original Mayo HCM Genotype Predictor using the 20 mm MLVWT cutoff [Mayo HCM Genotype Predictor (mm)].
Results
Study Population Demographic and Clinical Characteristics
A total of 78 patients met inclusion criteria for the present study. One patient had HCM gene panel testing with only three genes analyzed and a negative test result. For the purpose of this study, this patient was excluded from the analysis due to uncertainty of a true negative genetic test result, subsequently leading to a total study population of 77. Table 1 describes the demographic and clinical characteristics of our study population. In summary, there were more males (n = 57, 74%) than females, the mean age at time of genetic testing was 9.39 ± 5.98 years, and the mean MLVWT was 15.1 ± 7.7 mm. The average MLVWT z-score was 4.07 ± 2.33 and the mean ratio of maximal wall thickness to posterior wall thickness (MWTH:PWTH) was 1.70 ± 0.97. More than one-third of our study population had a sigmoid morphological subtype based on echocardiographic imaging. A positive family history of HCM was present in one-quarter of the population (n = 19, 25%). Most patients were of Caucasian race (n = 61, 79%) and 18% were African-American (n = 14). Two patients classified their race as other (3%).
Significant Predictors of a Positive Genotype
The significant predictors of a positive HCM genotype in this study (Table 1) were family history of HCM (P = 0.003), MLVWT (P = 0.03), MLVWT z-score (P = 0.01), and MWTH:PWTH (P = 0.036).
Genetic Testing Yield
In the present pediatric HCM cohort, 32 of 77 (42%) patients tested positive for at least one pathogenic variant. In this subset of patients with a positive HCM genetic test result, the majority had a single pathogenic variant identified in MYBPC3 (n = 15, 47%) or MYH7 (n = 10, 31%). Another 22% of patients with a positive genetic test result had a single pathogenic variant in ACTC1, PRKAG2, TNNT2, or TPM1 (n = 7). In addition, two patients of the 32 with a positive genotype (6%) had two pathogenic variants, with both having at least one pathogenic variant in MYBPC3 (Table 2 ). Supplemental Table 5 lists all variants deemed pathogenic/disease-causing or likely/presumed pathogenic/ disease-causing.
Of the two patients with genetic testing which included only five genes, one had a pathogenic variant and one had a VUS. One patient who had a gene panel consisting of 1 3
18 genes had a pathogenic variant identified in PRKAG2. PRKAG2 was included in genetic testing in the Toronto model but not the Mayo model. Otherwise, there were no pathogenic variants identified in genes not included in the Toronto and Mayo studies. Supplemental Table 6 lists genes analyzed on each panel and number of patients tested.
Variant Classification
In assessing pathogenicity, four variants were classified as uncertain by one submitter in ClinVar but were classified as pathogenic or likely pathogenic by ≥ 2 other submitters. These four variants were also reviewed in the ExAC Browser and three were not present, while one was found in 1 of 121,278 alleles. These four variants were included in the positive genotype group for this study. Two variants originally classified as pathogenic or likely pathogenic were not present in ClinVar or ExAC and remained in the positive genotype group. Mayo HCM Genotype Predictor (z-Score)
ROC analysis was performed to determine a cutoff value of MLVWT z-score for a positive genotype. The analysis revealed the optimal MLVWT z-score value to be 3.53 (AUC = 0.65, sensitivity = 72%, specificity = 53%, Fig. 1 ).
Model Performance
The predicted and observed positive genotypes were compared for the Toronto HCM Genotype Score Long Model (Fig. 2a) . Model calibration assessed with the Hosmer-Lemeshow goodness-of-fit test showed a P value of 0.36. Discrimination assessed by AUC was 0.72 (P < 0.001).
When the Tertiles Long Model with relative risk groups was used (Fig. 2b) , the model also demonstrated good calibration (Hosmer-Lemeshow goodness-of-fit test, P = 1) and slightly lower model discrimination (AUC = 0.68; P = 0.001). Figure 3a demonstrates the correlation between predicted and observed positive genotypes for the Mayo HCM Genotype Predictor (mm). The Hosmer-Lemeshow goodness-offit statistic gave a P value of 0.82 and model discrimination assessed by AUC was 0.67 (P = 0.004). When the 20-mm MLVWT marker was replaced with the optimal z-score of 3.53 determined from our study population, the Mayo HCM Genotype Predictor (z-score) again showed a relevant fit (Hosmer-Lemeshow goodness-of-fit statistic P = 0.71, Fig. 3b ). The AUC of 0.70 (P = 0.001) indicated a higher level of model discrimination than the Mayo HCM Genotype Predictor (mm), but both values were significantly different from 0.5.
Model Comparison
The Mayo HCM Genotype Predictor (mm) and the Mayo HCM Genotype Predictor (z-score) were compared to see if there was a distinct difference in how they discriminated between a pathogenic variant carrier and a non-carrier. The results showed that the original Mayo model performed just as well as the model using the optimal z-score cutoff value from our study population. Additionally, when both variations of the Mayo HCM Genotype Predictor were compared to the Toronto HCM Genotype Score, there was no significant difference in discrimination (Fig. 4) . This finding suggests that the Mayo HCM Genotype Predictor (mm), the Mayo HCM Genotype Predictor (z-score), and the Toronto HCM Genotype Score all performed similarly. MLVWT z-score ≥ 3.53 AUC = 0.65 Sensitivity = 72% Specificity = 53% Fig. 1 Optimal MLVWT z-score for Mayo HCM Genotype Predictor. The cutoff value for MLVWT z-score for a positive genetic test result was determined by receiver operating characteristic analysis. AUC area under the curve 
Discussion
The present study is the first evaluation of the predictive abilities and clinical usefulness of the Toronto HCM Genotype Score and the Mayo HCM Genotype Predictor in a pediatric population, to our knowledge. Overall, both existing models fit well to our pediatric HCM cohort. The Toronto Long Model showed suitable discrimination between a pathogenic variant carrier and a non-carrier. The Toronto Tertiles Long Model using relative risk groups showed slightly lower model discrimination than the original Toronto Long Model. The Mayo HCM Genotype Predictor (mm and z-score models) demonstrated slightly lower discrimination than the Toronto model, but were still valuable when applied to our study population. There was no significant difference in model discrimination when comparing the Mayo model variations to one another. Both models (mm and z-score) demonstrated adequate ability to discriminate between a carrier and non-carrier, despite our expectation. Overall, all prediction models performed similarly and accurately. From a clinical perspective, this finding suggests that the original Mayo model (mm) as well as the Toronto model are both useful in providing predictive risk counseling in the setting of pediatric HCM.
Several of our findings regarding genetic testing yield are consistent with previous adult and pediatric studies. The present study population had an overall genetic testing yield of 42%, which is higher than what is reported in the Toronto and Mayo groups' original studies. Most pathogenic variants were identified in MYBPC3 and MYH7, supporting the majority of shared causes of familial HCM in children and adults. In addition, 3% of our total study population had multiple pathogenic variants with at least one pathogenic variant identified in MYBPC3. This is relatively consistent with what has been previously reported [7, 30, 31] .
Previous studies also suggest that sigmoid septal morphology is more common in patients diagnosed with HCM at an older age and whose disease may not necessarily have a genetic etiology [22, 32] . However, in our study population of pediatric patients less than 18 years of age, sigmoid morphology was the most prevalent subtype (35% overall) with no statistically significant difference when comparing patients with positive versus negative HCM genotypes. This result is consistent with the Toronto group's findings and the Mayo group's validation study, which revealed a higher proportion of sigmoid septal morphologies than previously described.
In the present study, the significant predictors of a positive HCM genotype were family history of HCM, MLVWT, MLVWT z-score, and MWTH:PWTH. Furthermore, personal history of hypertension was not necessarily a negative predictor for a positive HCM genotype, although only six individuals in our cohort had this diagnosis. These minor differences in significant variables associated with positive genotype in our cohort compared to those in the Toronto and Mayo groups suggest that although the models ultimately proved useful in our study, there may be some considerations to improve upon these models in the pediatric population. As discussed previously, considering the Mayo HCM Genotype Predictor specifically, both the original model and model variation using MLVWT z-score in place of MLVWT (mm) performed similarly in our cohort overall. However, it is possible that for the younger individuals in our cohort with smaller cardiac size compared to older pediatric patients with body habitus approaching that of an adult, the MVLWT z-score variable may be the more appropriate variable to apply to adequately capture a more significant degree of hypertrophy. Our study did not allow for evaluation of model performance based on age. The presence of hypertension and age at diagnosis were variables included in generation of the genotype prediction score in both the Toronto and Mayo models. Given that all patients in our cohort have an age at diagnosis below the age assigned as cut-off for assigning points and the low prevalence of hypertension in our cohort, a model generated specifically from a pediatric population may weigh these variables differently, resulting in an altered scoring system for prediction of positive genotype.
In conclusion, we present findings which suggest that the Toronto HCM Genotype Score and the Mayo HCM Genotype Predictor can be usefully applied in a clinical pediatric HCM setting. The purpose of this study and seemingly previous studies is not to preclude patients from moving forward with genetic testing for HCM if they perhaps have a low probability of testing positive based on these models. Instead, the models may be used to aid cardiologists, geneticists, and genetic counselors in providing more detailed risk counseling for patients and families, and enhance patient decision-making regarding pursuit of gene panel testing for HCM.
Limitations
The results of the present study are based on a sample size of 77 seen at a single pediatric institution; therefore, our population may not be representative of all pediatric patients with HCM. Furthermore, a larger sample size would likely even the distribution of genotype scores, providing more generalizable results. Specifically, we had a small number of patients who had a genotype score of 4 or 5 using the Mayo HCM Genotype Predictor (mm). Further validation of the models in a pediatric population is recommended to better understand the models' applicability.
